Supplier · Large organisation

Bio Products Laboratory Ltd

Bio Products Laboratory Ltd has won 16 UK public contracts worth £911m since 19 Jan 2021. See its competitors in medical equipment & pharmaceuticals.

Company 07343036Companies House record Based in East of EnglandFirst contract 19 Jan 2021Latest contract 30 Apr 2025

Contracts: 16
Published value: £911mwhere stated
Without competition: 63%10 contracts
Won by SMEs: 0%of 16 with size known

Contracts won per month, last 24 months 10 contracts · busiest month April 2025

0510

Dec 24
Mar 25
6
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26

Biggest customers

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS") 10 contracts · £5.46m
NHS England 3 contracts · £905m
Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency 2 contracts · £2
UK Health Security Agency 1 contract · £1

What they supply

Medical equipment & pharmaceuticals 16 contracts · £911m

Competitors in medical equipment & pharmaceuticals

Sector overview

Medtronic Limited 156 contracts · £6.73bn
NHS Supply Chain Coordination Limited (NHSSC - SCCL) 117 contracts · £20.2m
B. Braun Medical Limited 107 contracts · £5.7bn
Johnson & Johnson Medical Limited 94 contracts · £3.38bn
Stryker UK Limited 70 contracts · £2.09bn
Boston Scientific Limited 67 contracts · £3.36bn

These are the suppliers with the most medical equipment & pharmaceuticals contracts in the last two years, which is where Bio Products Laboratory Ltd wins most of its work. They are not necessarily bidding for the same contracts. See the whole sector.

All contracts won by Bio Products Laboratory Ltd

Contracts won by Bio Products Laboratory Ltd
Date	Contract	Buyer	Value
30 Apr 2025	NP34925c Anti Rabies immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£544k
30 Apr 2025	NP34925b Tetanus immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£753k
30 Apr 2025	NP34925a Hepatitis B immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£549k
14 Apr 2025	NP34925a Hepatitis B immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£344k
14 Apr 2025	NP34925b Tetanus immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£494k
14 Apr 2025	NP34925c Anti Rabies immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£458k
19 Feb 2025	Immunoglobulins (2025): Lot 1 - Rabies immunoglobulin solution for injection	Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency	£1
19 Feb 2025	Immunoglobulins (2025): Lot 3 - Hepatitis B immunoglobulin 500IU	Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency	£1
19 Feb 2025	Immunoglobulins (2025)	UK Health Security Agency	£1
19 Dec 2024	NHS Framework Agreement for Human Albumin & Normal and Anti-D Immunoglobulin	NHS England	£905m
31 May 2024	NHS Framework - Blood Disorders including Haemophilia A and B - July 2024: CM/PHS/22/5661/11 Factor IX - High Purity Factor IX	NHS England	£1
31 May 2024	NHS Framework - Blood Disorders including Haemophilia A and B - July 2024: CM/PHS/22/5661/12 Factor X	NHS England	£1
19 Jan 2021	VZIG Varicella-Zoster immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£569k
19 Jan 2021	Anti Rabies immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£451k
19 Jan 2021	Tetanus immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£742k
19 Jan 2021	Hepatitis B immunoglobulin intramuscular use (IM) No competition	The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")	£554k

Contracts are matched to this supplier by company name as published in each notice. If a company appears under slightly different names, some of its contracts may be listed separately. How matching works.